Neuropsychiatric Disease and Treatment
October 1, 2026
Anita Słupska, Wiesław Jerzy Cubała, Damian Swieczkowski et al.
Objective: To synthesize evidence for intravenous racemic ketamine and regulated intranasal esketamine in adults with acute suicidal presentations; distinguish the outcomes these interventions have and have not been shown to change; and place any rapid response within a complete emergency suicide-care pathway. Methods: A narrative review of PubMed/MEDLINE-indexed literature was updated through...
Neuropsychiatric Disease and Treatment
August 9, 2025
Qing-Mei Li, Shuming Liu, Bangyong Qin et al.
Abstract This review systematically summarizes the research progress of ketamine and its interaction with specific brain regions in the context of neuropathic pain comorbid with depression. As a non-competitive inhibitor of N-methyl-D-aspartate (NMDA) receptors, Ketamine exerts complex mechanisms and controversial topic. The structure and function of NMDA receptors, as well as the binding sites...
Neuropsychiatric Disease and Treatment
August 1, 2025
Yue-Yue Zhang, Qianqian Cai, Lingshan Wang et al.
Background & Aims Esketamine, a promising treatment for treatment-resistant depression, has shown potential advantages over traditional antidepressants. However, its mechanisms remain unclear. This study explores how esketamine alleviates depressive behaviors through activation of the BDNF/TrkB/PI3K/AKT signaling pathway. Methods Using a Chronic Unpredictable Mild Stress (CUMS) rat model,...
Neuropsychiatric Disease and Treatment
2025
Daniel A Kinderlehrer
13 citations
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the...
Neuropsychiatric Disease and Treatment
2025
Ahmed Asad Raza, Ghazi Uddin Ahmed, Habiba Zafar et al.
6 citations
Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) are debilitating psychiatric conditions associated with significant psychosocial and economic burdens. Conventional antidepressants, particularly SSRIs and SNRIs, often produce inadequate responses and cause sexual dysfunction, contributing to poor adherence and diminished quality of life. This review aims to evaluate the...
Neuropsychiatric Disease and Treatment
2025
Ying Zhang, Zhaojuan Ke, Jie Luo et al.
3 citations
Major depressive disorder (MDD) has a high incidence and high risk of suicide. Electroconvulsive therapy (ECT) is a highly effective and rapid physical therapy for MDD but limited by adverse effects. Ketamine/esketamine are new emerging rapid antidepressants, which can synergize the efficacy and safety of ECT but come with other side effects. Binaural beat music (BBM) is a non-invasive...
Neuropsychiatric Disease and Treatment
2025
Yitong Ding, Zhengye Wang, Jing Huang et al.
3 citations
Although Dexmedetomidine (DEX) can induce sleep that resembles natural sleep, it has demonstrated limited efficacy in patients with comorbid insomnia and depression. On the other hand, Esketamine (ESK) has shown a potent antidepressant effect. Herein, we aimed to establish whether esketamine could enhance the therapeutic efficacy of DEX in treating patients with comorbid insomnia and...
Neuropsychiatric Disease and Treatment
2025
Zhaojuan Ke, Ying Zhang, Binyang Cai et al.
1 citation
Pregnancy leads to vulnerabilities and susceptibilities to mental disorders. Miscarriage, as an adverse pregnancy outcome, and following curettage for treatment, add the risks of further psychiatric disorders, including depression, anxiety, insomnia, etc., and current approaches to prevention are unsatisfactory. Ketamine and its S-enantiomer esketamine can prevent postpartum depression, and...
Neuropsychiatric Disease and Treatment
2024
Nadav Liam Modlin, Michael Creed, Maria Sarang et al.
18 citations
Post-traumatic stress disorder (PTSD) is associated with significant patient burden. While pharmacotherapies and evidence-based psychotherapy interventions (EBPI) are effective, studies consistently highlight inadequate outcomes and high treatment dropout. Psychedelic therapy (PT) has shown preliminary promise across difficult-to-treat conditions, including MDMA-assisted therapy for PTSD,...
Neuropsychiatric Disease and Treatment
2024
Xuemeng Chen, Rui Zhou, Lan Lan et al.
4 citations
Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esketamine may have potential advantages in improving the efficacy of ECT, and the strong affinity of this compound for NMDAR renders it a viable therapeutic option for the management of depression. This study aims to compare the effects of different...
Neuropsychiatric Disease and Treatment
2024
Chan Li, Chen Zhu, Genghong Tu et al.
4 citations
Ketamine is a drug of abuse worldwide and current treatments for ketamine abuse are inadequate. It is an urgent need to develop novel anti-addictive strategy. Since gut microbiota plays a crucial role in drug abuse, the present study investigates the impact and mechanisms of the gut microbiota in addictive behaviors induced by ketamine addiction. Conditioned place preference (CPP) was employed...
Neuropsychiatric Disease and Treatment
2024
Hui Song, Yang Luo, Lingzhi Fang
Esketamine nasal spray has emerged as a promising rapid-relief therapy for treatment-resistant depression (TRD) and suicide prevention. This review examines the chemical structure and pharmacodynamics of esketamine, highlighting its primary action on NMDA receptors and additional effects on AMPA receptors, opioid receptors, monoaminergic receptors, and inflammatory pathways. Despite the...
Neuropsychiatric Disease and Treatment
July 17, 2023
Cheng-Chuan Chen, Xiao-Bin Wang
Thank you very much for your attention and advice, as this is indeed a thought-provoking issue. Although the US Food and Drug Administration (FDA) has not yet recognized the advantages of ketamine in treating depression and preventing suicide, relevant research results show that ketamine also has a significant role in preventing suicide. In contrast, as the only drug approved by the FDA,...
Neuropsychiatric Disease and Treatment
July 12, 2023
Lucian Manu
Effects of Intravenous Sub-Anesthetic Doses of Ketamine and Intranasal Inhaled Esketamine on Suicidal Ideation: A Systematic Review and Meta-Analysis." This letter is not a rebuttal to the article but, rather, a response to further clarify a few points on the real-world use of ketamine and esketamine.
Neuropsychiatric Disease and Treatment
March 31, 2023
Xu Chen, Xuan Hou, Daisy Bai et al.
Purpose: This Phase 3, multicenter study (NCT03434041) was conducted in primarily Chinese patients with treatment-resistant depression (TRD) to support the registration of esketamine nasal spray in China. Patients and methods: This randomized, double-blind, active-controlled study was conducted in China and the United States (US) in patients with TRD (single or recurrent episode). Eligible...
Neuropsychiatric Disease and Treatment
March 14, 2023
Cheng-Chuan Chen, Na Zhou, Na Hu et al.
Purpose: Suicide is a major public health concern with currently no validated and efficacious treatments approved. Preliminary evidence suggests that intravenous ketamine has rapid and sustained antidepressant effects, making it a candidate with therapeutic potential for depressed patients at risk for suicide. We conducted a meta-analysis to evaluate the efficacy of ketamine and esketamine in...
Neuropsychiatric Disease and Treatment
2023
Kwonmok Ko, Ben Carter, Anthony J. Cleare et al.
26 citations
In psychedelic therapy, mystical as well as challenging experience may influence therapeutic outcome. However, predictors of such experience have not been sufficiently established. Determining predictors of their intensity is, therefore, potentially beneficial in targeting psilocybin therapy for depression. In a post hoc data analysis of a Phase 1, randomised, double-blind, placebo-controlled,...
Neuropsychiatric Disease and Treatment
2023
Allan H. Young, Mohamed Abdelghani, Mario F Juruena et al.
10 citations
Treatment-resistant depression (TRD) is associated with profound morbidity for patients, placing a significant burden on those affected, the health service and wider society. Despite this, TRD remains chronically underserved in terms of viable treatment options. To address this gap, an advisory panel of psychiatrists and clinical researchers with experience in managing TRD convened to develop...
Neuropsychiatric Disease and Treatment
2023
Iman Khan, Taimoor Asif Jaura, Alaa Tukruna et al.
5 citations
About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibility of their use as treatment options for obsessive-compulsive-disorder. The Scientific databases...
Neuropsychiatric Disease and Treatment
December 1, 2022
Peng Liu, Shanshan Zhang, Yun Liang et al.
16 citations
Objective: To evaluate the efficacy and safety of esketamine + antidepressant in treatment-resistant depression. Methods: We searched PubMed, Web of Science, Embase, CNKI, and Wanfang databases to obtain published information on esketamine + antidepressant from inception to July 2022. We searched for randomized controlled studies on the treatment of depression with a double-blind induction...
Neuropsychiatric Disease and Treatment
November 8, 2022
Nicole Porter, Leonard A Jason
Some individuals infected with SARS CoV-2 have developed Post-Acute Sequelae of SARS CoV-2 infection (PASC) or what has been referred to as Long COVID. Efforts are underway to find effective treatment strategies for those with Long COVID. One possible approach involves alternative medical interventions, which have been widely used to treat and manage symptoms of a variety of medical problems...
Neuropsychiatric Disease and Treatment
2022
Angie Ho Yan Lam, Yee Tak Derek Cheung, Kwan Ho Wong et al.
14 citations
Introduction: Studies have shown that rumination plays a significant mediating role between dispositional mindfulness (DM) and psychopathological symptoms in both clinical and non-clinical populations. However, no studies have examined this pathway in people with schizophrenia spectrum disorders (SSDs). Methods: A cross-sectional, clinician-administered survey was conducted among people with...
Neuropsychiatric Disease and Treatment
August 1, 2021
Alina Wilkowska, A. Włodarczyk, Maria Gałuszko‐węgielnik et al.
33 citations
Purpose Bipolar disorder is a chronic and recurrent condition often associated with treatment resistance and suicidality. There is an unmet need for effective treatment in this group of patients. Ketamine has been demonstrated to have antidepressant and antisuicidal properties in unipolar depression. Most of the available studies concern unipolar depression. Here, we present the efficacy and...
Neuropsychiatric Disease and Treatment
November 1, 2020
Alina Wilkowska, Łukasz P. Szałach, Wiesław Jerzy Cubała
31 citations
Abstract: Bipolar disorder (BD) is a psychiatric illness associated with high morbidity, mortality and suicide rate. It has neuroprogressive course and a high rate of treatment resistance. Hence, there is an unquestionable need for new BD treatment strategies. Ketamine appears to have rapid antidepressive and antisuicidal effects. Since most of the available studies concern unipolar depression,...
Neuropsychiatric Disease and Treatment
October 1, 2020
Joanna Szarmach, Wiesław Jerzy Cubała, Adam Włodarczyk et al.
15 citations
INTRODUCTION: Ketamine exhibits antidepressant properties in treatment-resistant depression (TRD) with some concern over its cardiovascular safety and tolerability issues. This paper reports on the cardiovascular safety in short-term intravenous ketamine treatment in TRD inpatients with major depressive disorder (MDD) and bipolar disorder (BP). MATERIALS AND METHODS: The observational study...